title: Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry.
abstract: The proportion of centres returning the ERA-EDTA Registry questionnaires has decreased considerably in recent years. Demographic information, based on the response rate of centres in 1994 (44%), does not allow reasonable projections for management of renal failure in Europe. To encourage the participation of non-responding centres, the timing was right to show the powerful impact of the ERA-EDTA Registry as a supra-national registry, by studying patients in renal replacement therapy (RRT) suffering from rare diseases. Four such diseases, Fabry's disease, nephropathy due to cyclosporin (CsA), nephropathy due to cisplatin and scleroderma, were studied using the records of 440665 patients on file up to 31 December 1993. There were 83 patients with Fabry's disease (0.0188%), 85 patients with CsA nephropathy (0.0193%), 120 patients with cisplatin nephropathy (0.0272%) and 625 patients with scleroderma (0.142%). Scleroderma was introduced as a primary renal disease (PRD) in the ERA-EDTA Registry in 1977. Seven patients were accepted for RRT in that year, whereas the number increased to over 50 new patients per year after 1986. More than half of the patients were aged over 55 years, and 68% of them were women. Survival rate of dialysis patients suffering from scleroderma was 22% at 5 years, compared to 51% in patients with standard primary renal diseases. The main causes of death were cardiovascular complications (41%), cachexia (15%) and infection (10%). Survival of first graft in a small number of 28 patients was 44% at 3 years, compared to 60% in standard PRD. Patient survival after first transplant, however, was higher by 32% at 3 years compared to that of dialysis patients. Cisplatin nephropathy was introduced as a PRD in the ERA-EDTA Registry in 1985, and since then six to 19 new patients have been accepted for RRT each year. The main reason for undergoing cisplatin treatment was ovarian (32%) and testicular cancer (21%), and the mean interval from treatment to RRT was 21.5 months, ranging widely from 0.1 to 131 months. Patient survival on dialysis was 22% at 5 years, compared to 51% in patients with standard PRD. Malignancy and cachexia accounted for over 60% of the total number of deaths. CsA nephropathy was introduced as a PRD in the ERA-EDTA Registry in 1985 and, despite its rarity, is of particular interest as a new iatrogenic entity resulting from CsA administration, mainly in solid organ transplantation. In 1985, two new patients commenced RRT in Europe, and the number increased to 59 in 1991-93. The main reason for undergoing CsA treatment was heart (68%) and liver transplant (22%), and the mean interval from treatment to RRT was 50.2 months, ranging from 5 to 90 months. Patient survival on dialysis was 46% at 4 years, compared to 58% in patients with standard primary nephropathies. Cardiovascular causes (48%) and infection (17%) were the main causes of death. Fabry's disease was introduced as a PRD in the ERA-EDTA Registry in 1985, and since the four to 13 new patients per year have commenced RRT in Europe. It is a sex-linked recessive disorder primarily affecting males (87%), and the mean age at start of RRT was 38 years. Proteinuria, skin lesions and painful paresthesiae were the most common presenting symptoms, and over 70% of the patients were hypertensive and had significant cardiovascular problems at RRT. Patient survival on dialysis was 41% at 5 years, compared to 68% in patients with standard primary nephropathies. Cardiovascular complications (48%) and cachexia (17%) were the main causes of death. Graft survival at 3 years in 33 patients was not inferior to that of patients with standard nephropathies (72% vs 69%), and patient survival after transplantation was comparable to that of patients under 55 years of age with standard PRD. (ABSTRACT TRUNCATED)
authors.forename: D
authors.initials: D
authors.lastname: Tsakiris
authors.forename: H K
authors.initials: HK
authors.lastname: Simpson
authors.forename: E H
authors.initials: EH
authors.lastname: Jones
authors.forename: J D
authors.initials: JD
authors.lastname: Briggs
authors.forename: C G
authors.initials: CG
authors.lastname: Elinder
authors.forename: S
authors.initials: S
authors.lastname: Mendel
authors.forename: G
authors.initials: G
authors.lastname: Piccoli
authors.forename: J P
authors.initials: JP
authors.lastname: dos Santos
authors.forename: G
authors.initials: G
authors.lastname: Tognoni
authors.forename: Y
authors.initials: Y
authors.lastname: Vanrenterghem
authors.forename: F
authors.initials: F
authors.lastname: Valderrabano
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000009:adverse effects; D016572:Cyclosporine / Q000009:adverse effects; D005060:Europe / Q000453:epidemiology; D000795:Fabry Disease / Q000453:epidemiology / Q000401:mortality / Q000628:therapy; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000453:epidemiology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012042:Registries; D017582:Renal Replacement Therapy / Q000401:mortality / Q000706:statistics & numerical data; D012595:Scleroderma, Systemic / Q000453:epidemiology / Q000401:mortality / Q000628:therapy; D015996:Survival Rate
chemical_list: D016572:Cyclosporine; D002945:Cisplatin